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Summary
Hepatocyte growth factor (HGF) binds the extracellular domain and activates the Met receptor to induce mitogenesis,
morphogenesis, and motility. The extracellular domain of Met is comprised of Sema, PSI, and four IPT subdomains. We
investigated the contribution of these subdomains to Met receptor dimerization. Our observations indicate that the Sema
domain is necessary for dimerization in addition to HGF binding. Treatment of Met-overexpressing tumor cells with
recombinant Sema in the presence or absence of HGF results in decreased Met-mediated signal transduction, cell motility,
and migration, behaving in a manner similar to an antagonistic anti-Met Fab. These data suggest that the Sema domain
of Met may not only represent a novel anticancer therapeutic target but also acts as a biotherapeutic itself.
Introduction (Furge et al., 2000; Hartmann et al., 1994; Ponzetto et al., 1996;
Royal and Park, 1995).
Met was shown to be transforming in a carcinogen-treatedHGF binds the extracellular domain of the Met receptor tyrosine
kinase (RTK) and regulates diverse biological processes such osteosarcoma cell line (Cooper et al., 1984; Park et al., 1986).
Met overexpression or gene amplification has been observedas cell scattering, proliferation, and survival. HGF-Met signaling
is essential for normal embryonic development, especially in in a variety of human cancers. For example, Met protein is
overexpressed at least 5-fold in colorectal cancers and reportedmigration of muscle progenitor cells and development of the
liver and nervous system (Bladt et al., 1995; Hamanoue et al., to be gene amplified in liver metastasis (Di Renzo et al., 1995;
Liu et al., 1992). Met protein is also reported to be overexpressed1996; Maina et al., 1996; Schmidt et al., 1995; Uehara et al.,
1995). Developmental phenotypes of Met and HGF knockout in oral squamous cell carcinoma, hepatocellular carcinoma, re-
nal cell carcinoma, breast carcinoma, and lung carcinoma (Jinmice are very similar, suggesting that HGF is the cognate ligand
for the Met receptor (Schmidt et al., 1995; Uehara et al., 1995). et al., 1997; Morello et al., 2001; Natali et al., 1996; Olivero et
al., 1996; Suzuki et al., 1994). In addition, overexpression ofHGF and Met also play a role in liver regeneration, angiogenesis,
and wound healing (Bussolino et al., 1992; Matsumoto and mRNA has been observed in hepatocellular carcinoma, gastric
carcinoma, and colorectal carcinoma (Boix et al., 1994; Kuni-Nakamura, 1993; Nusrat et al., 1994). Met undergoes proteolytic
cleavage into an extracellular subunit and membrane spanning yasu et al., 1993; Liu et al., 1992).
A number of mutations in the kinase domain of Met have subunit linked by disulfide bonds (Tempest et al., 1988). The
 subunit contains the cytoplasmic kinase domain and harbors been found in renal papillary carcinoma, which leads to constitu-
tive receptor activation (Olivero et al., 1999; Schmidt et al.,a multisubstrate docking site at the C terminus where adaptor
proteins bind and initiate signaling (Bardelli et al., 1997; Nguyen 1997, 1999). These activating mutations confer constitutive Met
tyrosine phosphorylation and result in MAPK activation, focuset al., 1997; Pelicci et al., 1995; Ponzetto et al., 1994; Weidner
et al., 1996). Upon HGF binding, activation of Met leads to formation, and tumorigenesis (Jeffers et al., 1997). In addition,
these mutations enhance cell motility and invasion (Giordanotyrosine phosphorylation and downstream signaling through
Gab and Grb2/Sos-mediated PI3 kinase and Ras/MAPK activa- et al., 2000; Lorenzato et al., 2002). HGF-dependent Met activa-
tion in transformed cells mediates increased motility, scattering,tion, respectively, which drives cell motility and proliferation
S I G N I F I C A N C E
Activation of the Met receptor tyrosine kinase induces multifunctional cellular responses. Aberrant Met activation, reported in several
cancers, has been shown to drive oncogenesis. This paper defines the Met Sema domain, which is shared by semaphorins and
plexins and is important for dimerization and ligand interaction, as necessary for receptor dimerization. Met-overexpressing tumor
cells treated with recombinant Sema or a Sema-recognizing anti-Met Fab inhibits ligand-dependent and -independent receptor
activation and downstream signaling. Our observations address the relevance of inhibiting Met receptor dimerization and elucidate
the domains important for this inhibition. Furthermore, our results illustrate the potential for targeting the Met Sema domain to generate
novel antineoplastic agents.
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and migration, which eventually leads to invasive tumor growth
and metastasis (Birchmeier et al., 2003; Jeffers et al., 1996;
Meiners et al., 1998).
Recently, Met has been shown to interact with other proteins
that drive receptor activation, transformation, and invasion. In
neoplastic cells, Met is reported to interact with 64 integrin,
a receptor for extracellular matrix components such as laminins,
to promote HGF-dependent invasive growth (Trusolino et al.,
2001). In addition, the extracellular domain of Met has been
shown to interact with a member of the semaphorin family,
plexin B1, and to enhance invasive growth (Giordano et al.,
2002). Furthermore, CD44v6, which has been implicated in tu-
morigenesis and metastasis, is also reported to form a complex
Figure 1. Schematic representation of Met deletion mutantswith Met and HGF and result in Met receptor activation (Orian-
Subdomain deletions of the Met extracellular domain were made from theRousseau et al., 2002).
N terminus and tagged after the TM region with V5/His. The Met signalMet is a member of the subfamily of RTKs that includes
peptide (S.P.) sequence was appended to the N terminus of each mutant.
Ron and Sea (Maulik et al., 2002). Prediction of the extracellular Abbreviations: Sema, semaphorin; PSI, plexin, semaphorin, integrin; IPT, im-
domain structure of Met suggests shared homology with the munoglobulin-like regions in plexins and transcription factors; and TM, trans-
membrane. The arrow on the Sema region points to the Met proteolyticsemaphorins and plexins. The N terminus of Met contains a
site.Sema domain of approximately 500 amino acids that is con-
served in all semaphorins and plexins. The semaphorins and
plexins belong to a large family of secreted and membrane
bound proteins first described for their role in neural develop-
as processed monomer (EC-M, 90 kDa) and unprocessed (*,
ment (Van Vactor and Lorenz, 1999). However, more recently
120 kDa) proteins. EC-WT crosslinking is detected by a shift
semaphorin overexpression has been correlated with tumor in-
from the lower (EC-M, 90 kDa) to an upper (EC-D, 180 kDa)
vasion and metastasis. A cysteine-rich PSI domain (also referred
migratory dimer as shown in Figure 2A. Met mutants lacking
to as a Met Related Sequence domain) found in plexins, sema-
the Sema domain did not display a similar shift. We note that
phorins, and integrins lies adjacent to the Sema domain followed
as expected, unprocessed EC-WT (*) Met did not display cross-
by four IPT repeats that are immunoglobulin-like regions found
linking, as sulfo-EGS is cell membrane impermeable. The intra-
in plexins and transcription factors. A recent study suggests
that the Met Sema domain is sufficient for HGF and heparin
binding (Gherardi et al., 2003).
Although the role of the Met kinase domain has been investi-
gated in detail, the extracellular domain of Met is poorly charac-
terized. Since HGF binds the extracellular domain of Met, re-
sulting in receptor activation, we wished to examine which
subdomain(s), if any, contributes to receptor dimerization. Dele-
tion mutants of the extracellular subdomains upon crosslinking
demonstrate that the Sema domain is not only necessary for
Met receptor association but is also essential for HGF binding.
In addition, we demonstrate that the Sema domain can inhibit
HGF-dependent and -independent receptor phosphorylation,
downstream signaling, and functional receptor activation. These
observations are the first to address the importance of the Sema
domain in Met receptor dimerization and potential therapeutic
applications in Met-overexpressing cancers.
Results
The Sema domain is necessary for Met
receptor crosslinking
To determine the contribution made by the extracellular domain
of Met to receptor dimerization and activation, subdomain dele-
Figure 2. The Sema domain is necessary for crosslinking Met
tions of Met were made as shown in Figure 1. Each deletion
A: The Met deletion mutants were transfected into 293 cells and exposed
mutant is flanked by the signal peptide (S.P.) at the N terminus to increasing concentrations of sulfo-EGS. 10 g of lysates were analyzed
and a C-terminal transmembrane region carrying a V5/His tag. by 4%–12% SDS-PAGE and immunoblotted with V5 antibody. EC-M and
EC-D represent EC-WT monomer and dimer, respectively. The asterisk indi-We tested the Met deletion mutants individually for the ability to
cates the presence of unprocessed EC-WT.crosslink using sulfo-EGS. Transfections of the V5/His-tagged
B: EC-WT-Flag and EC-WT-V5/His were cotransfected in 293 cells, subjecteddeletion mutants treated with increasing concentrations of
to increasing concentrations of sulfo-EGS, lysed, immunoprecipitated with
sulfo-EGS were lysed and analyzed on 4%–12% SDS-PAGE. either V5 or Flag antibodies, and analyzed by 8% SDS-PAGE. The immunopre-
cipitated samples were blotted with either Flag or V5 antibodies.In samples not treated with sulfo-EGS, EC-WT-V5/His appears
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Figure 3. HGF, scHGF (R494E), and anti-Met
5D5 antibody bind the Sema domain of Met
A: 293 cells were transfected with the indicated
Met-V5/His tagged construct, immunoprecipi-
tated with V5 antibody, analyzed by 4%–12%
SDS-PAGE, and immunoblotted with His anti-
body.
B: Top: The immunoprecipitates from A were
incubated with 5 g HGF. The samples were
analyzed by 4%–12% SDS-PAGE and immu-
noblotted with HGF antibody that recognizes
the  chain. 10 ng of input HGF served as a
positive control. Bottom: Immunoprecipitations
and immunoblotting were performed as in the
top panel using scHGF (R494E). As a positive
control, 15 ng scHGF (R494E) was analyzed with
the samples.
C: 293 cells were transfected with the indi-
cated constructs and analyzed by 4%–12%
SDS-PAGE. Lysates were immunoprecipitated
with anti-Met 5D5 antibody and immunoblot-
ted with His antibody (top) and reprobed with
Met C-12 antibody (bottom).
D: Endogenous Met is crosslinked in tumor cells.
Increasing concentrations of sulfo-EGS were
added to 293, H441, MDA-MB-435, and A549
cells that had been serum starved. A549 cells
were also incubated with 10 g/ml HGF prior to
crosslinking. Lysates were immunoblotted with
Met C-12 antibody. As a control, full-length
Met-V5/His was transfected into 293 cells, cross-
linked, and immunoblotted with V5 antibody.
cellular single-chain precursor of Met is detected as a proteolyti- with chain-HGF antibody shows that HGF bound EC-WT alone
(Figure 3B, top). Since HGF did not bind the Sema-deletedcally cleaved protein on the cell surface (Giordano et al., 1989).
We used sulfo-EGS as a crosslinking agent because of its limited mutants, our observations suggest that the Sema domain is
necessary for HGF binding.cell permeability and examined the effects of crosslinking mem-
brane-inserted processed Met receptor. Single-chain HGF containing an R494E mutation [scHGF
(R494E)] binds and inhibits activation of the Met receptor (LokkerTo address if membrane bound extracellular Met formed
homodimers, cells were cotransfected with EC-WT-V5/His and et al., 1992). scHGF (R494E) was also examined for binding to
the Met extracellular domain. Transfected Met deletion mutantsEC-WT-Flag and crosslinked with sulfo-EGS. Cells were lysed,
immunoprecipitated with V5 antibody, analyzed on 8% SDS- were lysed, incubated with scHGF (R494E), and analyzed as
above. We observed scHGF (R494E) binding only to EC-WTPAGE, and immunoblotted with either Flag or V5 antibodies.
The immunoblots display an upper migratory form (EC-D,180 and not the Sema-deleted mutants (Figure 3B, bottom). These
observations were corroborated with coimmunoprecipitationkDa) containing EC-WT-Flag and EC-WT-V5/His (Figure 2B),
indicating that both forms of EC-WT are crosslinked and coim- experiments where both HGF and scHGF (R494E) bound to
recombinant EC-Met and Sema domain proteins (data notmunoprecipitated. A reverse immunoprecipitation using Flag
antibody showed similar results confirming our prior observation shown). Thus, we confirm that the Sema domain of Met is the
HGF interaction site (Gherardi et al., 2003; Stamos et al., 2004).(Figure 2B). Residual noncrosslinked EC-WT-Flag (EC-M) is also
detected in the V5 immunoprecipitates but shifts to the upper
migratory form with the addition of increased sulfo-EGS (Figure 5D5 monoclonal antibody binds the Sema
domain of Met2B). Collectively, our crosslinking studies reveal that extracellu-
lar membrane bound Met homodimers are formed when the Monoclonal antibodies were raised to the extracellular domain
of Met in an attempt to identify antagonistic Met antibodies.Sema domain is present.
One of these antibodies, anti-Met 5D5, bound Met and inhibited
HGF binding. The Fab fragment of anti-Met 5D5 (anti-Met 5D5-HGF and scHGF (R494E) bind to the Sema domain
HGF is secreted as an inactive single-chain precursor and is Fab) was shown to inhibit HGF-driven Met phosphorylation, cell
proliferation, and tumor growth (R. Schwall, personal communi-cleaved by extracellular proteases into an  and  chain (Naka
et al., 1992). The cleaved disulfide-linked  and  chains of HGF cation). We tested binding of anti-Met 5D5 to the Met extracellu-
lar domain. Cells were transfected with the Met deletion con-bind the Met receptor with high affinity (Bottaro et al., 1991;
Naldini et al., 1991). We tested the Met deletion mutants for structs or mock transfected as indicated. These cell lysates
were immunoprecipitated with anti-Met 5D5 and immunoblottedtheir ability to bind HGF. Cells were transfected with EC-WT,
S, P, IPT3, or TM or were mock transfected (Figure 3A), and with His antibody. Only the Sema-containing EC-WT bound to
anti-Met 5D5 (Figure 3C, top). All transfected proteins werecell lysates were incubated with HGF. Immunoprecipitation with
V5 antibody followed by 4%–12% SDS-PAGE and detection detected in the lysates as seen in Figure 3A (data not shown),
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and endogenous Met was immunoprecipitated by anti-Met 5D5 In addition, we examined inhibition of Met activation by
rSema in the absence of HGF. For comparison, anti-Met 5D5-(Figure 3C, bottom). Thus, our data suggest that anti-Met 5D5
binds the Sema domain of Met. Since anti-Met 5D5-Fab acts Fab that acts as a Met receptor antagonist was used in our
functional studies. A549 cells were serum starved and treatedas an antagonist in addition to binding the Sema domain, we
used it as a control in our functional studies. with anti-Met 5D5-Fab or rSema. Treatment with rSema or anti-
Met 5D5-Fab caused an inhibition of ligand-independent Met
phosphorylation and phospho-MAPK levels compared to mock-Crosslinking of endogenous Met in tumor cell lines
Since our results suggest that the Sema domain is associated treated control (Figures 4C and 4D). Similarly, H441 and MDA-
MB-435 cell lines were also treated with anti-Met 5D5-Fab andwith two functions, namely HGF binding and receptor dimeriza-
tion, we next examined the role of the Met Sema domain in rSema in the absence of HGF (Figures 4C and 4D); the decrease
in MAPK phosphorylation followed a trend similar to that of ourdimerization with and without the involvement of HGF binding.
The levels of HGF expressed in 293 (embryonic kidney), A549 previous observations with A549 cells. These results suggest
that rSema not only inhibits ligand-dependent and -independent(lung carcinoma), H441 (lung adenocarcinoma), and MDA-MB-
435 (breast carcinoma) cell lines were determined by RT-PCR Met phosphorylation but also affects downstream MAPK sig-
naling.and Western blot analysis. MDA-MB-435 and H441 cells did
not have detectable HGF RNA or protein, while A549 and 293 Met deletion mutants were also examined for their ability
to attenuate endogenous Met signal transduction. Cells werecells expressed HGF RNA and had barely detectable HGF pro-
tein in lysates and conditioned media (data not shown). To transfected with the Met deletion mutants (Figure 5A); lysates
were immunoprecipitated with a C-terminal Met antibody anddetermine if Met expressed in various tumor cell lines could
crosslink in the absence of HGF, cells were maintained in serum- immunoblotted with phospho-tyrosine antibody. EC-WT trans-
fectants showed attenuation of Met tyrosine phosphorylationfree media with 0.5% BSA for the duration of the experiment.
These cell lines were crosslinked with sulfo-EGS as before and and phospho-MAPK compared to mock-treated controls (Fig-
ures 5B and 5C). Sema-deleted transfectants, while showinglysates were analyzed by 4%–12% SDS-PAGE followed by im-
munoblot with Met antibody. In the absence of crosslinking some attenuation of phospho-Met, did not show a decrease
in downstream MAPK phosphorylation (Figures 5B and 5C).reagent, Met appears as processed (Met-M) and unprocessed (*)
proteins as seen previously in crosslinking studies with EC-WT Together, these observations confirm that the Sema domain is
necessary for Met activation, corroborating our previous results(Figure 2A). In each cell line, even at 0.1 mM sulfo-EGS, a shift
from Met-M to an upper migratory form (Met-D) was observed with rSema inhibition of Met signaling (Figure 4).
(Figure 3D). Increased concentrations of crosslinking agent en-
hanced the shift of Met-M to the Met-D form. Consistent with Cell migration is inhibited by rSema
and anti-Met 5D5-Fabour previous observation, intracellular unprocessed Met does
not crosslink upon sulfo-EGS treatment. In comparison, A549 H441 cells were used in a scrape assay as a measure of Met-
mediated cell motility (Lorenzato et al., 2002). H441 cells growncells were incubated with HGF and crosslinked as described
before. Immunoblotting for Met reveals a higher migratory form to high density were scraped in each well on Day 0 and main-
tained in serum-free media with 0.5% BSA for the duration ofin the presence of HGF when compared to Met-D seen in the
absence of HGF (Figure 3D). The data suggest that crosslinked the experiment. To examine the effect of rSema on cell motility
in the presence of ligand, cells were treated with 0, 0.1, 0.5, orMet dimers are formed in the absence of HGF and are shifted
further due to HGF binding. 5 g/ml rSema plus 20 ng/ml HGF. Cells treated with HGF alone
closed the gap completely by Day 1. In comparison, cells treated
with rSema in the presence of HGF retained the gap in a dose-Inhibition of Met signaling in tumor cells
with rSema and anti-Met 5D5-Fab dependent manner (Figure 6A). The data suggest that rSema
inhibits Met-mediated cell motility in the presence of HGF. WeSince our data suggest that the Sema domain is necessary
for Met dimerization, we generated recombinant Sema (rSema) also examined the effect on cell motility with rSema or anti-
Met 5D5-Fab in the absence of HGF. Serum-starved cells wereprotein, which included the Sema and PSI domains of the Met
receptor (Stamos et al., 2004), and examined the functional treated with either 10 g/ml rSema or anti-Met 5D5-Fab. As
controls, cells were also mock treated or treated with 100 ng/mlconsequences on Met signaling. Human tumor cells were
treated with increasing concentrations of rSema and analyzed HGF. On Day 2, the gap in mock-treated wells closed completely
while a gap remained in the rSema-treated cells (Figure 6B).for Met tyrosine phosphorylation and downstream activation of
mitogen-activated protein kinase (MAPK) upon HGF stimulation. The gap in anti-Met 5D5-Fab-treated cells also remained visible,
to a lesser extent. HGF-treated cells had closed the gap by DayA549 cells were serum starved and incubated with increasing
concentrations of rSema in the presence of HGF. Cell lysates 1 as seen in Figure 6A and remained as such on Day 2 (data
not shown). The data suggest that cell motility mediated bywere harvested, immunoprecipitated with a C-terminal Met anti-
body, and immunoblotted with phospho-tyrosine antibody. A endogenous Met activation is inhibited by both rSema and anti-
Met 5D5-Fab in the absence of HGF.decrease in Met phosphorylation was observed with increasing
amounts of rSema in the presence of HGF compared to HGF A transwell assay with MDA-MB-435 cells was used to mea-
sure Met-driven cell migration (Coltella et al., 2003) in the pres-stimulation alone (Figures 4A and 4B). Similarly, phosphorylation
of MAPK decreases upon treatment with increasing concentra- ence and absence of HGF. Addition of HGF to these cells results
in 4-fold increase in migration over mock-treated wells. Ations of rSema in the presence of ligand. H441 and MDA-MB-
435 cell lines were also treated with rSema and HGF in a similar dose-dependent inhibition of HGF-driven cell migration is ob-
served with the addition of rSema (Figure 7A). In the absencemanner, and a dose-dependent decrease in phospho-MAPK is
observed (Figures 4A and 4B). of HGF, migration is consistently decreased by the addition of
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Figure 4. Met signal transduction is inhibited by rSema and anti-Met 5D5-Fab
A: A549 cells were kept serum-free and treated with 0, 5, 10, 50, or 100 g/ml of rSema with 10 ng/ml HGF for 10 min for phospho-Met and phospho-MAPK
analysis. Lysates were immunoprecipitated with Met C-12 antibody and immunoblotted with phospho-tyrosine antibodies to detect phosphorylated Met
followed by immunoblotting with Met antibody. H441 and MDA-MB-435 cells were treated with 0, 5, 10, or 100 g/ml rSema plus 5 or 10 ng/ml HGF,
respectively, for 5 min. Proteins were detected with phospho-MAPK and reprobed with MAPK antibodies.
B: The data in A were quantified using NIH Image software and are represented as bar graphs in the left panels comparing the ratio of phosphorylated
to unphosphorylated proteins between each sample. The right panels represent data from another experiment.
C: A549, H441, and MDA-MB-435 cells were kept serum-free and treated with 10 g/ml rSema or anti-Met 5D5-Fab. The samples were immunoblotted with
phospho-tyrosine, Met, phospho-MAPK, or MAPK antibodies.
D: The data in C were quantified and presented as in B.
rSema and anti-Met 5D5-Fab to a lesser extent (Figure 7B). The Discussion
data correlate with the scrape assay results in the H441 cell
The Sema domain resides in the extracellular region of sema-line. Activation of Akt was also examined in H441 and MDA-
phorins and their receptors, plexins, and serves as a receptor/MB-435 cells used in the cell motility and migration assays. We
ligand recognition site (Tamagnone et al., 1999). Previous publi-observed a dose-dependent decrease in Akt phosphorylation
cations of the crystal structures of Sema3A and Sema4D sug-with increasing concentrations of rSema in the presence of HGF
gest that these Sema domains form seven-bladed -propeller
(data not shown). The data correlate with our observations that
structures that are important for homodimerization (Antipenko
rSema can inhibit cell motility in the presence of ligand. Taken et al., 2003; Love et al., 2003). Recently, the crystal structure
together, these observations suggest that the Sema domain is of the Sema domain of Met in complex with the  chain of HGF
capable not only of inhibiting Met activation, but also of blocking was determined and confirmed that the Sema domain of Met
downstream effects of cell motility and migration in both ligand- forms a seven-bladed -propeller structure that binds HGF
(Stamos et al., 2004). We report here experimental evidencedependent and -independent contexts.
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Figure 5. The extracellular domain of Met attenuates Met signal transduction
A: A549 cells were transfected with the indicated constructs. The expression of the Met mutants was detected by immunoblotting with V5 antibody.
B: Left: Lysates from A were immunoprecipitated with Met C-12 antibody and immunoblotted with phospho-tyrosine antibody. The membrane was reprobed
with Met antibody. Right: Lysates were immunoblotted with phospho-MAPK and then reprobed with MAPK.
C: The data in B were quantified using NIH Image software and are represented as bar graphs in the left panels comparing the ratio of phosphorylated
to unphosphorylated proteins for each sample. The right panels represent data from another experiment.
that strongly support a role for the Sema domain in Met receptor lar domain of each receptor have been implicated in receptor
dimerization (Robertson et al., 2000). In the Met receptor, ourdimerization. Our data show that crosslinking of Met occurs
only in the presence of the Sema domain, suggesting a neces- study shows that neither the cysteine-rich PSI domain nor the
four IPT domains exhibit crosslinking in the absence of the Semasary role for the Sema domain in receptor dimerization. In addi-
tion, crosslinking of Met was observed in the absence of HGF, domain, suggesting that these regions may not be necessary
for Met dimerization. Furthermore, Met interaction with plexinindicating that Met receptor in these tumor cell lines may dimer-
ize without ligand stimulation. B1 was unaltered despite deletion of the PSI domain of Met
(Giordano et al., 2002). Although the rSema used in our func-The crystal structure of Sema3A suggests that four interac-
tion “loops” in the Sema domain are important to establish tional studies contained a Sema and PSI domain (Stamos et
al., 2004), our own crosslinking studies and the reported PSIthe interface between Sema3A dimers (Antipenko et al., 2003).
Alignment of the Sema3A sequence with Met reveals that one domain deletion in plexin B1 (Giordano et al., 2002) strongly
suggest that the Sema domain plays a dominant role in theseloop resides close to the proteolytic cleavage site between R307
and S308 in the Met Sema domain. Further studies will be interactions in the absence of the PSI domain. Attempts to
generate internal PSI or IPT deletions resulted in expressionrequired to determine the precise role of these loops and their
potential involvement in Met dimerization. of nonprocessed Met that could not be used in our studies.
Therefore, we cannot formally exclude a role for the PSI andIn our current cell-based study, we observe Sema domain-
mediated homophilic interactions of the Met receptor in the IPT domains in Met dimer formation or some other mechanism
such as auto-inhibition of dimerization as reported for EGFRabsence of HGF. However, previous reports suggest that Met
also interacts with CD44v6, 64 integrin, and plexin B1 (Gior- (Ferguson et al., 2003). Resolution of the crystal structure of
extracellular Met would shed more light on these complex inter-dano et al., 2002; Orian-Rousseau et al., 2002; Trusolino et al.,
2001). Based on our studies, it is tempting to speculate that actions.
Crystallographic studies of ligand-receptor complexes ofMet association with plexin B1 could occur through these highly
conserved Sema domains. In addition, overexpression of both RTKs have revealed several structural insights. Both Flt-1 and
TrkA utilize dimerization of ligands for receptor dimerizationMet and semaphorins has been described in cancers and inva-
sive metastases, tempting further speculation that any potential and activation (Wiesmann et al., 1997, 1999). In FGFR, heparin
bound FGF ligand drives receptor dimerization (Plotnikov etinteractions could be mediated through the Sema domains.
However, the role of these molecules and the mechanisms that al., 1999). In contrast, the EGF:EGFR (epidermal growth factor
receptor) complex homodimerizes through the receptor, inde-mediate heteromeric interactions in these pathological contexts
need further elucidation. CD44v6 and 64 are not known to pendent of ligand-ligand interaction (Garrett et al., 2002; Ogiso
et al., 2002). The interaction of Met and HGF is less clear,contain Sema domains. Therefore, interactions with other pro-
tein motifs mediated through the Sema and/or the PSI or IPT although a recent report suggests that Met, HGF, and heparin
exist as a 1:1:1 complex (Gherardi et al., 2003). Our cell-baseddomains may be important in initiating specific biological re-
sponses (Bertotti and Comoglio, 2003) and cannot be excluded studies differ from these reported in vitro observations since
cellular components such as the extracellular matrix (ECM) areas a possibility.
In RTKs such as fibroblast growth factor receptor 2 (FGFR2) present in our study and may have considerable influence on
receptor dimerization in vivo. Since the ECM contains lamininsand RET, disulfide bonding between cysteines in the extracellu-
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Figure 7. Cell migration is inhibited by rSema and anti-Met 5D5-Fab
A: MDA-MB-435 cells were pre-incubated with increasing concentrations
of rSema and seeded into the upper chambers of a transwell plate in
serum-free media. The lower chambers contained 100 ng/ml HGF with the
exception of mock-treated wells.
B: Cells were pre-incubated with 10 g/ml anti-Met 5D5-Fab or increasing
concentrations of rSema and then seeded into the upper chamber of each
transwell in serum-free media. The lower chamber contained serum-free
media. The data are representative of three independent experiments per-
formed in duplicate. The migrating cells were stained with crystal violet and
Figure 6. rSema and anti-Met 5D5-Fab inhibit cell motility the absorbance of eluted cells was measured at 560 nm.
A: H441 cells were scraped on Day 0 and treated with increasing concentra-
tions of rSema plus HGF in serum-free media. The scrapes were photo-
graphed on Day 0 and Day 1. A representative data set of three indepen-
dent experiments is shown. corroborate our data (M. Zhang, personal communication).B: H441 cells were scraped and treated with mock, rSema, or anti-Met 5D5-
Since anti-Met 5D5-Fab also inhibits ligand-independent recep-Fab in serum-free media over the course of 2 days. Photographs were taken
on Day 0 and Day 2. Four independent experiments were carried out and tor activation as observed in our findings, we speculate that
a representative data set is shown. in addition to HGF competition, anti-Met 5D5-Fab may block
receptor dimerization by steric hindrance. Likewise, rSema also
inhibits ligand-independent and -dependent Met activity, sug-
gesting a role for rSema as an effective Met inhibitor. Similarand other components responsible for cellular interactions (Gi-
inhibitory activity has been described for the c-kit receptor (Levancotti and Ruoslahti, 1999), it is likely that all proteins that
et al., 1992). The role of the Met Sema domain in dimerizationfacilitate Met dimerization may not yet be identified.
in a ligand-independent context addressed in this study differsWe report that the Sema domain is sufficient for interaction
from the role of the Ron Sema domain. While the Ron Semawith HGF, confirming previous observations (Gherardi et al.,
domain competes for binding with MSP to inhibit Ron activity,2003) and demonstrate that rSema inhibits ligand-driven Met
it does not appear to inhibit Ron receptor dimerization (Angeloniactivation. Thus, it is likely that rSema effectively inhibits HGF-
et al., 2004). Our functional studies carried out in the presencedependent Met activation by binding HGF. Furthermore, it sug-
and absence of HGF demonstrates that the Met Sema domaingests that HGF-dependent Met-expressing tumors could also
inhibits both ligand-dependent and –independent receptor acti-be targeted by rSema in a similar manner to Ron Sema domain-
vation. These data suggest that although the structural motifsmediated inhibition of ligand-dependent receptor activation (An-
and binding interactions of Met and Ron may be similar, thegeloni et al., 2004). We speculate that the Sema-HGF interaction
in vivo contexts may specify differing homophilic interactions.site differs from the Met dimerization interface, since our cross-
In this report, we identify the Met Sema domain as a potentiallinking studies show that ligand-independent Met dimers shift
inhibitor of not only ligand-dependent but also ligand-indepen-further when bound to HGF (Figure 3D). These data imply that
dent Met receptor activation in a manner similar to anti-Metthe dimerization interface and the HGF interaction site are non-
5D5-Fab. Antagonistic antibodies that target the extracellularoverlapping.
domain of Met prevent growth of Met-driven tumors in vivo (R.In addition, we demonstrate that the Sema domain is neces-
Schwall, personal communication). Likewise, our data suggestsary for binding anti-Met 5D5. Similar observations of Met 5D5
binding to rSema by surface plasmon resonance experiments that the Sema domain of Met blocks receptor activation in tumor
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Cruz), 1:1,000 MAPK (Cell Signaling), 1:500 HGF- (145) (Santa Cruz),cells by inhibiting MAPK phosphorylation, cell motility, and mi-
1:1,000 P-MAPK (Cell Signaling), 1:1,000 His (Cell Signaling), or 1:1,000gration. These observations point to the exciting prospect of
phospho-tyrosine 4G10 (Upstate) antibodies overnight at 4C with rocking.treating Met-overexpressing tumors not only by targeting the
Secondary antibodies conjugated to HRP against mouse or rabbit IgG were
Sema domain of Met but also by utilizing the Sema domain
used at 1:5,000–10,000 dilution (Amersham). Proteins were detected by
itself as a biotherapeutic. enhanced chemiluminescence (ECL-Plus, Amersham). For membranes that
were stripped and reprobed, stripping buffer was added (100 mM 2-mercap-
Experimental procedures toethanol, 2% SDS, 62.5 mM Tris-HCl [pH 6.7]) for 30 min at 65C with
occasional agitation prior to re-incubation of primary antibodies. Densitome-
Constructs and recombinant proteins try analysis of Western blots was performed using NIH Image 1.63 program
Extracellular subdomain deletions of cMet were constructed using conven- (http://rsb.info.nih.gov/nih-image). The data are represented as a ratio of
tional PCR methods. N-terminal primers containing the start of Sema, PSI, phosphorylated to nonphosphorylated protein.
first IPT, or fourth IPT domains flanked by a KpnI site were paired with a
C-terminal primer up to Met residue 959 flanked by a StuI site. cMet was
Covalent affinity crosslinking analysis
used as template and the PCR fragments for each clone were inserted
Crosslinking studies were performed as previously described with modifica-into pCR-Blunt II-TOPO vector using the Zero Blunt TOPO PCR cloning
tions (Blechman et al., 1995). A549, H441, MDA-MB-435, and 293 cells werekit (Invitrogen) according to manufacturer’s instructions. The clones were
serum starved for 2 hr in media with 0.5% BSA. The media was removedconfirmed by DNA sequencing. The constructs were then subcloned into
and replaced with PBS. Cells were then treated with the crosslinking agentpcDNA3.1 V5/His vector (Invitrogen) via KpnI and EcoRV to add a tag at
sulfo-EGS (Pierce) at increasing concentrations according to the manufac-the C terminus. The signal peptide of Met was added via the HindIII and
turer’s instructions. Sulfo-EGS is known to predominantly crosslink reactiveKpnI sites at the N terminus of each clone. Each clone was digested with
groups in lysines that are present throughout the extracellular domain ofHindIII and EcoRV and subcloned into pRK5TKneo vector via HindIII and
Met. Similarly, 293 cells were plated into 6-well plates and transfected withPmeI. For EC-WT-Flag and EC-WT-V5/His clones, an N-terminal primer
0.1–4 g of the indicated constructs using Lipofectamine 2000 (Invitrogen).containing a HindIII site was paired with a C-terminal primer up to Met
24 hr later, the media was replaced with PBS and cells were crosslinked withresidue 959 flanked by a StuI site. EC-WT-V5/His was subcloned via HindIII/
sulfo-EGS. Cells were then lysed with 1% NP40 lysis buffer with protease andStuI into the HindIII/EcoRV sites of pcDNA3.1 V5/His and then subcloned
phosphatase inhibitors. 10 g of lysates in reducing sample buffer wereinto pRK5TKneo as described above. For EC-WT-Flag, the PCR fragment
then analyzed immediately on 8% or 4%–12% Tris-glycine gels, transferredwas ligated to pCR-Blunt II-TOPO vector. Oligonucleotides containing a Flag
to nitrocellulose membranes, and blocked with 5% milk for 1 hr. Membranestag sequence were inserted between StuI and KpnI. EC-WT-Flag was then
were probed with 1:1,000 C-terminal Met C-12 or 1:5,000 V5 antibody over-subcloned into pRK5TKneo via HindIII and EcoRV/ScaI. Full-length Met
night at 4C with rocking. After incubation of 1:5,000 secondary antibodies,containing a V5/His tag was constructed by PCR primers flanked by BsrGI
proteins were detected with ECL-Plus. Full-length Met-V5/His, EC-WT-Flag,and XhoI sites using Met as template. The BsrGI/XhoI-digested PCR product
and EC-WT-V5/His constructs were cotransfected and crosslinked as de-was then inserted into the vector of EC-WT-V5/His to produce full-length
WT Met-V5/His. Recombinant HGF and anti-Met 5D5-Fab were provided scribed. For EC-WT binding studies, 500 g of crosslinked lysate was immu-
by R. Schwall (Genentech). scHGF(R494E) was produced in mammalian noprecipitated with either V5 or Flag antibody, analyzed on 8% Tris-glycine
cells by S. Avella as described previously (Peek et al., 2002). Recombinant gels, transferred to nitrocellulose membranes, and immunoblotted with either
Sema (and PSI domain) was prepared as described previously (Stamos et 1:5,000 V5 or 1:1,000 Flag (Sigma) antibodies. Proteins were detected with
al., 2004). Attempts to make recombinant Sema domain alone did not yield ECL-Plus.
protein as reported previously for Sema3A (Antipenko et al., 2003).
Scrape assay
Immunoprecipitation and Western blot analysis H441 cells were seeded at a density of 4.5  104 cells/well in a 96-well plate
Cell lines were obtained from American Type Culture Collection (ATCC). with 10% FBS in 50:50 DMEM:F12. The next day (Day 0), a single scrape
293 cells were maintained in DMEM supplemented with 10% FBS (Sigma), was made in the confluent monolayer in each well as described previously
penicillin/streptomycin (GIBCO), and 2 mM glutamine. A549, H441, and (Lorenzato et al., 2002). The media was replaced with media containing
MDA-MB-435 cells were maintained in 50:50 DMEM/F12 (Cellgro) supple- 0.5% BSA. For HGF-dependent studies, 0, 0.1, 0.5, or 5 g/ml rSema was
mented with 10% FBS, penicillin/streptomycin, and 2 mM glutamine. Cells pre-incubated with HGF for 1 hr prior to addition to cells. Photographs were
were transfected with 1–12 g of the indicated constructs using Lipofectam- taken on Day 0 and Day 1, when the gap in HGF-treated cells had closed
ine 2000 (Invitrogen) according to manufacturer’s instructions. 24 hr later, completely. For HGF-independent studies, cells were treated with mock, 10
cells were harvested with 1% NP40 lysis buffer (50 mM Tris [pH 7.45],
g/ml anti-Met 5D5-Fab, or 10 g/ml rSema. The scrape was monitored
150 mM NaCl, and 1% Nonidet 40) with Complete protease inhibitor cocktail
and photographed daily. Representative results are shown for Day 0 and
tablet and phosphatase inhibitor cocktail 2 (Roche and Sigma, respectively).
Day 2.
Cell debris was centrifuged and the supernatant was precleared with Protein
A Sepharose (Sigma) or Protein G-Plus agarose beads (Santa Cruz) for 1 hr.
Migration assayFor HGF binding studies, 500 g of lysates were incubated with 5 g scHGF
Transwell migration assays were carried out as previously described with(R494E) or HGF and immunoprecipitated with 1 g of V5 antibody overnight
modifications (Coltella et al., 2003). MDA-MB-435 cells were seeded at 1.2at 4C with rotation followed by incubation with Protein G-Plus beads for
105 cells in 50:50 DMEM:F12 media containing 0.5% BSA to the upper2 hr. For anti-Met 5D5 binding studies, 10 g/ml of anti-Met 5D5 was
chamber of each transwell (Costar) that had been previously coated withincubated with 500 g of transfected lysates overnight followed by incuba-
10 g/ml collagen type IV (Sigma). Cells were pre-incubated for 10 min withtion with Protein G-Plus beads as before. For Met tyrosine phosphorylation
0, 5, 10, or 20 g/ml rSema. As control, some samples were pre-incubatedand MAPK phosphorylation studies, cells were serum starved for 2 hr with
with 10 g/ml anti-Met 5D5-Fab. The cells were distributed to the upper0.5% BSA in the medium. In HGF-dependent studies, cells were incubated
chambers of the transwell plate. The lower chambers contained media withwith 0, 5, 10, 50, or 100 g/ml rSema for 1 hr prior to addition of 5 or 10
0.5% BSA. Similarly, migration assays were carried out with rSema in theng/ml HGF for 5 or 10 min. For HGF-independent studies, cells were treated
presence of HGF. Cells were pre-incubated for 10 min with 0, 5, 10, or 100with 10 g/ml anti-Met 5D5-Fab or rSema for 1 hr. To detect phosphorylated
g/ml rSema and added to the upper chambers as before. Each lowerMet, lysates were immunoprecipitated with 20–40 l of Met (C-28) agarose
chamber contained media supplemented with 100 ng/ml HGF with the ex-conjugate (Santa Cruz) overnight at 4C. For all samples, 2 sample buffer
ception of mock-treated wells. The next day, the cells were fixed with 4%(Invitrogen) with 10 mM DTT was added, boiled for 2 min, and analyzed on
paraformaldehyde and stained with 0.5% crystal violet. Cells that migrated4%–12% Tris-glycine gels (Invitrogen). Proteins were transferred to nitrocel-
to the lower chamber were stained and solubilized with 10% acetic acidlulose membranes, blocked with 5% nonfat milk or BSA for 1 hr, and then
probed with 1:5,000 V5 (Invitrogen), 1:10,000 C-terminal Met (C-12) (Santa and the absorbance was measured at 560 nm in a microplate reader.
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